No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial

Digestive and Liver Disease

Volumn 45, Issue 4, 2013, Pages 323-329

  Schuchmann, Marcus ^a   Kittner, Jens M ^a   Schlaak, Jörg F ^b   Klass, Dietmar M ^c   Eisenbach, Christoph ^d   Berg, Thomas ^e   Trautwein, Christian ^f   Günther, Rainer ^g   Zeuzem, Stefan ^h   Gösseringer, Roger ⁱ   Ehrlich, Anne ^j   Neumann, Konrad ^k   Wachtlin, Daniel ^j   Sprinzl, Martin F ^a   Zimmermann, Tim ^a   Böcher, Wulf O ^a,l   Galle, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ ROCHE INNOVATION CENTER MUNICH   (Germany)

^j Interdisciplinary Centre for Clinical Trials   (Germany)

^k Institute for Biometry and Clinical Epidemiology   (Germany)

^l BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

All trans retinoic acid; Chronic hepatitis C; Efficacy; Genotype 1; Mathematical model of viral kinetics; Non response; Randomised clinical trial; Safety; Tolerability

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RETINOIC ACID; RIBAVIRIN;

ADULT; ALOPECIA; ANTIVIRAL THERAPY; APHTHOUS STOMATITIS; ARTICLE; ATTENTION DISTURBANCE; CHEILITIS; CHILL; CLINICAL PROTOCOL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; EAR DISEASE; EPISTAXIS; ERYTHEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; GINGIVA BLEEDING; HEPATITIS C; HUMAN; HYPERHIDROSIS; INNER EAR DISEASE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MUCOSAL DRYNESS; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NIGHT SWEAT; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING; XEROSTOMIA;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TRETINOIN; VIRAL LOAD;

EID: 84875257651     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.11.006     Document Type: Article

References (38)

1. Mühlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
2. Sweeting M.J., De Angelis D., Brant L.J., et al. The burden of hepatitis C in England. Journal of Viral Hepatitis 2007, 14:570-576.
3. Shiffman M.L., Di Bisceglie A.M., Lindsay K.L., et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023. [discussion 1947].
4. Jensen D.M., Marcellin P., Freilich B., et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Annals of Internal Medicine 2009, 150:528-540.
5. Poynard T., Colombo M., Bruix J., et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:1618-1628. e1612.
6. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011, 364:1207-1217.
7. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011, 364:2417-2428.
8. Lippman S.M., Kessler J.F., Meyskens F.L. Retinoids as preventive and therapeutic anticancer agents (part I). Cancer Treatment Reports 1987, 71:391-405.
9. Park J.H., Tallman M.S. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology 2011, 25:733-741.
10. Morbitzer M., Herget T. Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. Journal Biological Chemistry 2005, 280:8831-8841.
11. Kelner M.J., Bagnell R.D., Montoya M.A., et al. Structural organization of the human gastrointestinal glutathione peroxidase (GPX2) promoter and 3'-nontranscribed region: transcriptional response to exogenous redox agents. Gene 2000, 248:109-116.
12. Kast R.E. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-a treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma ND. Therapy 2008, 1515-1519.
13. Kato H., Takahasi K., Fujita T. RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunological Reviews 2011, 243:91-98.
14. Hamamoto S., Fukuda R., Ishimura N., et al. 9-cis retinoic acid enhances the antiviral effect of interferon on hepatitis C virus replication through increased expression of type I interferon receptor. Journal of Laboratory and Clinical Medicine 2003, 141:58-66.
15. Böcher W.O., Wallasch C., Höhler T., et al. All-trans retinoic acid for treatment of chronic hepatitis C. Liver International 2008, 28:347-354.
16. Patatanian E., Thompson D.F. Retinoic acid syndrome: a review. Journal of Clinical Pharmacy and Therapeutics 2008, 33:331-338.
17. Vesanoid 10mg (tretinoin). Package insert 2008. Grenzach-Wyhlen, Germany: Roche Pharma AG.
18. de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Reviews Cancer 2010, 10:775-783.
19. Ellis C.N., Krach K.J. Uses and complications of isotretinoin therapy. Journal of the American Academy of Dermatology 2001, 45:S150-S157.
20. Fallon M.B., Boyer J.L. Hepatic toxicity of vitamin A and synthetic retinoids. Journal of Gastroenterology and Hepatology 1990, 5:334-342.
21. Neumann A.U., Lam N.P., Dahari H., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
22. Herrmann E., Lee J.-H., Marinos G., Modi M., et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351-1358.
23. Layden-Almer J.E., Ribeiro R.M., Wiley T., et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343-1350.
24. Copegus (Ribavirin) package insert 2007, Roche Pharma AG, Grenzach-Wyhlen, Germany.
25. Pegasys (pegylated interferon alpha-2a) Package insert 2007, Roche Pharma AG, Grenzach-Wyhlen, Germany.
26. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
27. Chevaliez S., Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology 2011, 35(Suppl. 1):S31-S41.
28. Fujinaga H., Tsutsumi T., Yotsuyanagi H., et al. Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology 2011, 81(Suppl. 1):11-17.
29. Choi J., Ou J.H.J. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. American Journal pf Physiology-Gastrointestinal and Liver Physiology 2006, 290:G847-G851.
30. Okuda M., Li K., Beard M.R., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
31. Gong G., Waris G., Tanveer R., et al. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:9599-9604.
32. Ramya D., Siddikuzzaman, Manjamalai A., et al. Chemoprotective effect of all-trans retinoic acid (ATRA) on oxidative stress and lung metastasis induced by benzo(a)pyrene. Immunopharmacology and Immunotoxicology 2012, 34:317-325.
33. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine 2010, 362:1675-1685.
34. + T cell-mediated immunity. Journal of Experimental Medicine 2011, 208:1767-1775.
35. Chen Q., Mosovsky K.L., Ross A.C. Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo. Clinical and Vaccine Immunology 2011, 18:1015-1020.
36. Hall J.A., Grainger J.R., Spencer S.P., et al. The role of retinoic acid in tolerance and immunity. Immunity 2011, 35:13-22.
37. Gu W., Zhao G., Shi F. Acitretin-induced retinoic acid syndrome. Journal of the American Academy of Dermatology 2011, 65:e148-e149.
38. Liu D., Cao F., Yan X., et al. Retinoic acid syndrome in a patient with psoriasis. European Journal of Dermatology 2009, 19:632-634.